Xoma Lands Orphan Drug Status for Eye Disease Treatment

Xoma lead drug, gevokizumab, was granted orphan drug status for an inflammatory eye disease. Gevokizumab, or XOMA-052, is a monoclonal antibody that focuses on shutting down inflammation brought on by a type of cell-signaling protein called interleukin-1 beta.
San Francisco Business Journal